Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
June 27 2023 - 9:20AM
Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the
"Company"), a precision oncology company with a novel
phosphoprotein and protein assay for breast cancer in the process
of merging with IMAC Holdings, Inc. (NASDAQ: BACK), today announces
the appointment of Faith Zaslavsky as its new Chief Executive
Officer. Ms. Zaslavsky, who has served as the Company’s President
and Chief Operating Officer since December 2022, will assume this
role effective June 26, 2023, replacing Mick Ruxin, M.D., who will
transition to Theralink’s Chief Medical Officer.
“I am very excited to hand the reins to Faith as
we take the strategic step to merge with IMAC,” commented Dr.
Ruxin. “As we begin a new chapter of shifting our focus from
research and development to commercialization for the Company,
Faith checks all the boxes as an excellent fit for our future. She
is a highly accomplished executive having previously served as
president and general manager of the oncology business unit of a $2
billion dollar genetics company. A respected executive with a
passion for health care innovation, Faith has unparalleled
leadership ability and knowledge of international business, which
will be instrumental as we move forward to help save lives with the
Theralink assay for a spectrum of cancers.”
Ms. Zaslavsky has over 23 years of experience in
the field of genomics and multiple commercialization successes to
her credit. She has made significant contributions to the
development of new genomic offerings and the application of
genomics to clinical practice, ultimately making genomics more
accessible to patients and healthcare providers while building
corporate value. Amongst other successes, Ms. Zaslavsky has been
instrumental in the commercialization of tests that detect
mutations in BRCA1 and BRCA2 genes associated with increased risk
of breast and ovarian cancer; provided oversight for tests used to
detect mutations in genes associated with Lynch syndrome, a
hereditary cancer syndrome; and launched an oncology suite of
solutions providing guidance in therapeutic decision making.
Cumulatively, these tests inform thousands of physicians, and help
treat or prevent countless cases of cancer.
As Chief Executive Officer of Theralink, Ms.
Zaslavsky will be tasked with leveraging her prior successes to
spearhead commercialization of the Theralink® Reverse Phase Protein
Array assays, a next generation of genomic technology used to guide
personalized cancer therapeutics.
Faith Zaslavsky stated, “On behalf of our
executive leadership team, I want to thank Mick for his innumerable
contributions and dedicated years of service to Theralink. Since
his appointment to CEO in 2018, Mick has led the Theralink team
through critical product development and business model
transformations, which has enabled the Company to expand our
product and intellectual property portfolio. I am honored to follow
in his footsteps and embrace the opportunity to lead Theralink as
we bring proprietary, life-changing testing solutions to physicians
and patients facing a cancer journey.”
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based,
precision medicine company with a nationally CLIA-certified and
CAP-accredited laboratory located in Golden, Colorado. Through its
unique and patented phosphoprotein and protein biomarker platform
and laboratory developed tests (LDTs), Theralink's technology
targets multiple areas of oncology and drug development. In
addition to the Company's first assay for advanced breast cancer,
Theralink is actively working on a second assay that is planned to
be pan-tumor for solid tumors across multiple tumor types such as
ovarian, endometrial, pancreatic, liver, head and neck, colorectal,
lung, prostate, among others. Theralink provides precision oncology
data through its powerful Theralink® Reverse Phase Protein Array
assays to assist the biopharmaceutical industry and clinical
oncologists in identifying likely responders and non-responders to
both FDA-approved and investigational drug treatments. Theralink
intends to help improve cancer outcomes for patients, help reveal
therapeutic options for oncologists, and support biopharmaceutical
drug development by using a beyond-genomics approach to molecular
profiling that directly measures drug target levels and activity.
For more information, please visit www.theralink.com.
Contact: Al kucharchukAl.Kucharchuk@theralink.com
IMAC (NASDAQ:BACK)
Historical Stock Chart
From Apr 2024 to May 2024
IMAC (NASDAQ:BACK)
Historical Stock Chart
From May 2023 to May 2024